Hengrui Pharma targets obesity drug launch after test success
The Chinese drug company is looking to break into the big league for weight-loss treatments after its injection demonstrated sustained weight loss in Phase Three trials Key Takeaways: Participants receiving…
BRIEF: Hengrui executive to sell nearly 500,000 A-shares
Pharmaceutical company Jiangsu Hengrui Pharmaceuticals Co. Ltd. (1276.HK; 600276.SH) said on Sunday that executive director and senior vice president Sun Jieping will sell up to 476,700 of his A-shares in…
3SBio hits the big time with $6 billion cancer drug deal
The pharma giant Pfizer has bought international rights to the experimental cancer therapy and will take a $100 million equity stake in the Chinese drug developer Key Takeaways: The mega…
BRIEF: Hengrui Pharma to raise up to $1.3 billion in Hong Kong IPO
Jiangsu Hengrui Pharmaceuticals Co. Ltd. (1276.HK; 600276.SH) launched its Hong Kong IPO on Thursday, aiming to sell 225 million shares at a price range of HK$41.45 to HK$44.05 per share,…
Recent Articles
Hengrui Pharma targets obesity drug launch after test success
1278.HK
600276.SHG
BRIEF: Hengrui executive to sell nearly 500,000 A-shares
1276.HK
600276.SHG
BRIEF: Hengrui Pharma to raise up to $1.3 billion in Hong Kong IPO
1276.HK
600276.SHG
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK -
Medtide launches IPO to bulk up its weight-loss business
3880.HK
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
- RNA drug developer Ribo Life targets fresh funding channel
-
CSPC Pharma teases big bucks deals after earnings miss
1093.HK
- Will Trump’s drug order put the brakes on China’s overseas pharma drive?
-
BRIEF: Hengrui Pharma surges in trading debut for $1.25 billion IPO
1276.HK 600276.SHG
